Barriers to the use of warfarin: potential solutions.
McAnulty
John H
JH
Oregon Health & Science University, Portland, Oregon, USA. mcanultj@ohsu.edu
D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004363:Drug Utilization; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D019934:International Normalized Ratio; D010349:Patient Compliance; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin